Literature DB >> 3930991

Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain.

E A Neuwelt, P A Barnett, C I McCormick, E P Frenkel, J D Minna.   

Abstract

In the dog, osmotic opening of the blood-brain barrier (BBB) in the posterior circulation via the vertebral artery and in the anterior circulation via the internal carotid artery was utilized to increase the delivery of three substances of varying molecular weight to the central nervous system. The cerebrospinal fluid (CSF) concentration of all three agents dramatically increased after BBB opening. In contrast to methotrexate, Evans blue-albumin and monoclonal antibody (MAb) concentrations in CSF were 6-fold greater when given after posterior rather than anterior circulation BBB opening. Conversely, MAb delivery to brain parenchyma was optimized after osmotic BBB modification via the carotid artery. This suggests that, with higher molecular weight substances, osmotic barrier opening has a differential effect on the blood-brain vs. blood-CSF barriers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930991     DOI: 10.1227/00006123-198509000-00004

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  16 in total

Review 1.  Blood-brain barrier and new approaches to brain drug delivery.

Authors:  W M Pardridge; R J Boado; K L Black; P A Cancilla
Journal:  West J Med       Date:  1992-03

2.  Influence of mannitol on the penetration of teicoplanin into infected CSF of experimental Staphylococcus aureus meningitis of rabbits.

Authors:  G Manquat; J P Stahl; I Pelloux; M Micoud
Journal:  Infection       Date:  1990 Mar-Apr       Impact factor: 3.553

3.  Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases.

Authors:  E A Neuwelt; S A Dahlborg
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

4.  Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note.

Authors:  H A Riina; J Knopman; J P Greenfield; S Fralin; Y P Gobin; A J Tsiouris; M M Souweidane; J A Boockvar
Journal:  Interv Neuroradiol       Date:  2010-03-25       Impact factor: 1.610

5.  Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells.

Authors:  P Hülper; S Veszelka; F R Walter; H Wolburg; P Fallier-Becker; J Piontek; I E Blasig; M Lakomek; W Kugler; M A Deli
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

6.  Monitoring proteins using in vivo near-infrared time-domain optical imaging after 2-O-hexyldiglycerol-mediated transfer to the brain.

Authors:  Petra Hülper; Christian Dullin; Wilfried Kugler; Max Lakomek; Bernhard Erdlenbruch
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

7.  Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.

Authors:  C C Chio; S J Lin; M T Lin
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics.

Authors:  E C de Lange; M B Hesselink; M Danhof; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

9.  Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.

Authors:  Shamik Chakraborty; Christopher G Filippi; Tamika Wong; Ashley Ray; Sherese Fralin; A John Tsiouris; Bidyut Praminick; Alexis Demopoulos; Heather J McCrea; Imithri Bodhinayake; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2016-03-05       Impact factor: 4.130

10.  Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain.

Authors:  Bernhard Erdlenbruch; Claudia Schinkhof; Wilfried Kugler; Dagmar E H Heinemann; Jochen Herms; Hansjörg Eibl; Max Lakomek
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.